Despite a surge in FDA-cleared radiology AI tools, very few qualify for reimbursement due to lack of supporting clinical studies.
Key Details
- 1Radiology comprises roughly 80% of all FDA-cleared medical AI algorithms.
- 2Only one CPT category 1 payment code for newer AI tools exists today; a second will be added in January 2026.
- 3Both reimbursement codes are specific to cardiac imaging AI applications.
- 4Hundreds of approved algorithms lack reimbursement due to insufficient clinical evidence of patient benefit.
- 5Experts attribute the problem to a disconnect between regulatory clearance and payment policy.
Why It Matters
Without reimbursement, the financial incentives for clinical adoption of imaging AI are limited, slowing broader deployment of these technologies. Bridging the gap between regulatory approval and payment is critical for real-world impact of AI in radiology.
Source
Radiology Business
Related News
•HealthExec
AI Reimbursement, Biomedical Research, and Exec Survey Highlight Healthcare Trends
Healthcare AI adoption is rising, but ROI measurement and clinical impact remain key challenges.
•HealthExec
Senate Vote Fails to Block AI Medicare Prior Authorization Pilot
A Senate vote failed to halt the WISeR AI-based prior authorization pilot for traditional Medicare claims.
•AuntMinnie
Radiology Leads FDA AI Device Approvals Over Three Decades
Radiology accounts for 76% of all FDA-cleared AI/ML-enabled medical devices as of the end of 2025.